The topic of drug pricing and reimbursement took center stage last year, as the Trump administration, Capitol Hill, state legislatures, government agencies, and industry trade groups and stakeholders sought to advance competing ideas of reform. Join us as we recap notable developments from 2018 and outline current trends that are predicted to shape events in 2019.
Our review will address a host of legal reforms—both proposed and implemented—at the state and federal levels that implicate drug pricing and reimbursement. Subjects will include the Trump administration’s Blueprint to Lower Drug Prices, Medicare Parts B and D, manufacturer copay coupons, drug rebates, the 340B Drug Discount Program, and the Drug Supply Chain Security Act.
Have a question? Please email Wesley Hayden at firstname.lastname@example.org.